Event Banner

CVS and Walgreens say they will start dispensing abortion pills weeks before Supreme Court hears case


[UPDATE] The Supreme Court will hear a case later this month regarding whether the Food and Drug Administration (FDA) illegally relaxed safeguards on chemical abortion pills, but that isn’t enough to deter pharmacy retailers CVS and Walgreens, who both confirmed that they would begin dispensing the pills in the coming weeks.

CVS and Walgreens told the New York Times on Friday that they had received certification to dispense mifepristone following the guidance of the FDA. Both retailers will begin selling mifepristone at select locations and then expand to states where abortion is legal.

“We are beginning a phased rollout in select locations to allow us to ensure quality, safety and privacy for our patients, providers and team members,” said Fraser Engerman, a spokesman for Walgreens.

Amy Thibault, a spokeswoman for CVS, said, “We continually monitor and evaluate changes in state laws and will dispense mifepristone in any state where it is or becomes legally permissible to do so.”

Chemical abortion involves a two-drug regimen: mifepristone, which starves the fetus of progesterone, eventually killing it; and misoprostol, which expels the fetus from the woman’s body. The rules surrounding these drugs once required women to go to their doctor’s office for an exam; receive the first pill; and come back for follow-up visits. However, the FDA loosened its rules around the use of the pills in 2016 and then began allowing women to obtain the pills through telemedicine visits and through the mail during the COVID lockdowns.

In some states, a woman is still required to see a doctor in-person to get a prescription for the abortion-inducing pills. If pharmacies do not carry the drugs, doctors must keep the pills in stock. But if doctors don’t have the drugs, they can write a prescription during the office visit, and certified pharmacies like CVS and Walgreens will fill it.

The decision by CVS and Walgreens to dispense the drugs comes just weeks before the Supreme Court is scheduled to review two consolidated cases on this issue: U.S. Food and Drug Administration v. Alliance for Hippocratic Medicine and Danco Laboratories v. Alliance for Hippocratic Medicine.

The Court will hear oral arguments on March 26 and is expected to issue its ruling in June.

Both cases deal with the safety of the abortion pills and whether the FDA illegally circumnavigated its own protocols in loosening the restrictions on how the pills are prescribed and dispensed.

The plaintiffs, several medical groups led by Alliance for Hippocratic Medicine, first brought the suit in 2022, alleging that the FDA violated the Administrative Procedures Act (APA) when it approved mifepristone and that the regulatory agency’s relaxation of restrictions on both drugs resulted in women experiencing even more complications. These included excessive bleeding and doctors having to step in and finish “incomplete” abortions in which all parts of the child had not been expelled.

The U.S. District Court for the Northern District of Texas overturned the FDA’s approval of the drugs, but after the FDA appealed the decision to the U.S. Court of Appeals for the Fifth Circuit, the initial approval of the drugs was left in place, but the looser restrictions were rescinded.

The appellate ruling reduces the timeframe in which the drugs can be provided, dropping it from 10 weeks’ gestation to 7. It also bans doctors from dispensing the drugs via the mail, requiring instead an in-person visit to a physician, as well as a follow-up visit.

The appellate court decision is stayed until the Supreme Court hears the case.

The FDA appealed the ruling to the Supreme Court, arguing that the courts did not take into account the FDA’s scientific expertise and its claims that the drugs are proven to be safe. Those claims were met with suspicion by the 5th Circuit after noting that the FDA relied on faulty data to justify its conclusion that the drugs were safe.

Danco also appealed its case to the Supreme Court, where the Court decided to consolidate the cases. Danco’s attorneys said in their court filing, “For the women and teenage girls, health care providers, and States that depend on FDA’s actions to ensure safe and effective reproductive health care is available, this case matters tremendously,” adding that “for the pharmaceutical and biotechnology industry, permitting judicial second-guessing of FDA’s scientific evaluations of data will have a wildly destabilizing effect.”

Erin Hawley, senior counsel for Alliance Defending Freedom (ADF), which represents the plaintiffs in both cases, said in a statement:

“Women should have the ongoing care of a doctor when taking high-risk drugs. The FDA’s own label for abortion drugs says that roughly one in 25 women who take them will end up in the emergency room. But the FDA recklessly removed its original safeguards like in-person doctor visits leaving women to suffer serious complications alone. It’s appalling that the FDA would eliminate even the initial in-person visit to check for life-threatening conditions like ectopic pregnancy based on studies it said were ‘not adequate.’ Women deserve better, which is why dozens of states, members of Congress, doctors, and advocacy groups joined with us in urging the Supreme Court to hold the FDA accountable for endangering women’s health.”


{Published on August 18, 2023}  A panel for the U.S. Court of Appeals for the Fifth Circuit upheld an injunction barring abortion-inducing drugs from being mailed to patients while also restoring prior safeguards in a unanimous ruling earlier this week.

In 2022, four medical groups and four doctors filed suit against the FDA and Danco Laboratories, the manufacturer of the two abortion pills: mifepristone and misoprostol.

The doctors alleged that the FDA had violated the Administrative Procedures Act (APA) when it approved mifepristone in 2000 and that the expansion of the usage of the drug in 2016 and 2021 resulted in doctors being forced to perform abortions or treat women who had taken the drugs.

The U.S. District Court for the Northern District of Texas sided with the doctors and issued an injunction against the pill’s approval and the FDA’s regulatory changes.

In considering the FDA’s appeal, the Fifth Circuit affirmed the district court’s injunction on all but the FDA’s approval of mifepristone in 2000 and the approval of the generic drug in 2019.

In relation to the 2016 modifications, the Fifth Circuit said the doctors are substantially likely to succeed on the merits of the case. In 2016, the FDA increased the maximum gestational age from seven weeks to ten, allowed non-physicians to prescribe mifepristone; removed the requirement that the administration of misoprostol and the subsequent follow-up appointment be conducted in person; eliminated prescribers’ obligation to report adverse events; changed the method of administration for misoprostol from swallowing the medicine (oral) to placing it inside the cheek (buccal); and changed the dose of mifepristone (reduced from 600 mg to 200 mg) and misoprostol (increased from 400 mcg to 800 mcg).

The panel wrote that the FDA did not study the cumulative effects of the changes nor consider whether the agency needed to continue collecting adverse reaction data.

The FDA decided that the data did not have to be collected “because the risks associated with mifepristone were well known”; it also argued that the change was insignificant because Danco remained obligated to report serious adverse events.

The ruling, however, revealed that Danco’s data came from the FDA’s voluntary reporting system. Doctors testified that the reporting system is so difficult and takes so long to complete most doctors don’t use it. What’s more, the FDA relied on Danco’s data knowing that Danco was using data already available to the agency — data which the FDA admitted was unreliable. One doctor testified that in 2010 Planned Parenthood reported 1,530 events, whereas 664 reactions were reported that year on the voluntary system for the entire nation.

In addition, the FDA relied on its voluntary reporting system to approve its 2021 changes, including allowing women to receive the drug without an in-person doctor visit and allowing the drug to be mailed rather than be administered in the doctor’s office.

The Court chastised the agency, writing,

“…because of the 2016 Amendments, FDA no longer had access to perhaps the best source of data: the prescribers. The agency is responsible for its own inability to obtain probative data; it cannot then cite its lack of information as an argument in favor of removing further safeguards. As the motions panel aptly put it: ‘It’s unreasonable for an agency to eliminate a reporting requirement for a thing and then use the resulting absence of data to support its decision.’”

The Court also ruled that the FDA used studies that it admitted were not adequate to show that dispensing the drugs by mail was safe. The panel wrote,

“Especially in light of the unreliability of the adverse-event data, it was not reasonable for FDA to depend on the published literature to support its decision.”

In a partial dissent, Judge James Ho reasoned that the FDA’s original approval of mifepristone in 2000 was unlawful. The FDA used an authority that allowed it to approve the drug to “treat serious or life-threatening illnesses,” even though, as Ho noted, “pregnancy is plainly not an illness.”

Judge Ho’s response to the FDA and Danco’s view of the district court ruling is important to understanding this case. He wrote:

“In this appeal, neither the FDA nor Danco is content to simply argue that the district court erred. They disparage the ruling as ‘an unprecedented judicial assault on a careful regulatory process.’ The ‘non-expert’ district court issued an ‘unprecedented order countermanding the scientific judgment of the Food and Drug Administration.’ Their message is simple: The scientists at the FDA can do no wrong. So courts have no business reviewing their actions.”

Ho retorted that Congress has instructed the judiciary to review the legality of actions by agencies. He continued that Congress could have exempted FDA, but it did not. “Scientists have contributed an enormous amount to improving our lives. But scientists are human beings just like the rest of us. They’re not perfect…None of us are. We all make mistakes. And the FDA has made plenty.”

Ho detailed only some of the multitude of poor decisions the FDA has made. One example was the FDA’s approval in 1941 of DES (diethylstilbestrol) for women to treat certain pregnancy and postpartum conditions. Before the approval, the FDA knew the drug caused cancer and issues with sexual development in lab animals. The FDA did not rescind its approval of DES for human use until 2000, after the drug was shown to cause cancer and significantly increase the risk of infertility, stillbirth, miscarriage, and neonatal death.

In the last two decades the FDA has had numerous errors. The Journal of the American Medical Association noted that in the ten years following FDA’s approval of mifepristone, almost one-third of all therapeutics it approved experienced safety issues.

Ho added that many courts have ruled FDA actions unlawful, writing, 

“The scientists at the FDA deserve our respect and our gratitude, but not our blind deference. That would defy Congress’s clear directive that courts conduct independent legal review of FDA action under the APA.”

Americans should celebrate that the court got it mostly right and has added safeguards back to these dangerous drugs, but they also need to use this as a lesson.

The FDA is not infallible and is not immune to political ideology. Their actions show that they do not care about women’s health. The message they tout about chemical abortion drugs is that they are safe and have almost no risks, but all the data and testimony shows otherwise.

Many doctors who provide these pills don’t even offer women emergency services if they experience a problem. Women take the pill, go home, and suddenly find themselves in excruciating pain, excessively bleeding, and dealing with an incomplete abortion. Women then must go to the hospital where a doctor must treat them and finish the abortion by removing the remaining parts of the fetus that has not been expelled and stanching the bleeding.

Women must remember that the FDA knows that hospitalization is a serious risk; neither it nor Danco disputes this. In clinical trials, over 7 percent of American women who were administered chemical abortion pills had to go to the hospital. Yet that never stopped the FDA from first approving the drug and then removing safeguards, including allowing abortion pills by mail. Women who take these pills often have no idea what’s involved or what they are at high risk of experiencing.

What other drug would be approved if more than 7 out of 100 times it was administered it resulted in a trip to the emergency room? When the left says that these drugs should be available to every woman without a doctor, they are risking women’s well-being. And no pro-abortion slogan about how abortion is healthcare will make that any different.

If you like this article and other content that helps you apply a biblical worldview to today’s politics and culture, consider making a small donation here.

Not Just Conservative.

Christian conservative news and issues that matter. Curated just for you!

Tired of your social media feed being censored?

For more timely, informative, and faith-based content, subscribe to the Standing for Freedom Center Newsletter

Join us in our mission to secure the foundations of freedom for future generations
Donate Now
Completing this poll entitles you to receive communications from Liberty University free of charge.  You may opt out at any time.  You also agree to our Privacy Policy.